Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals — Proxy Contest (October 2019)

43 slides from Progenics Pharmaceuticals's proxy contest presentation, Oct 22, 2019

  1. Slide 1: Creating Shareholder Value Through the Advancement of Cancer Treatment

    Progenics Creating Shareholder Value Through the Advancement of Cancer Treatment Progenics Find Fight and Follow

  2. Slide 2: Paving the Best Path Forward for Long-Term Shareholder Value

    © Her 8D, Come. Cf & a Paving the Best Path Forward for Long-Term eS, Shareholder Value me se, Progenics

  3. Slide 3: Safe Harbor Statements

    Safe Harbor Statements Important Information For Investors And Stockholders {esoprowme epson or uteaton ner estes lows sch uscaon no eget scieeaho be made tsb mes oa reps ache eqrenens ecient US Fetes In conmetan wth he Vln cae Slt, routs a tite contr easton statnent and aomsanng WATE cn revcatin ct

  4. Slide 4: Safe Harbor Statements (Cont'd)

    Safe Harbor Statements (Cont’d) Cautionary Statement Regarding Forward-Looking Statements row hora facts are forwardioohingstatemers tha ele Pogeics curen pespective of esting ends andinermation sof e dae chs communication and ine sateets regarding Powis Sate an Gpeation lane and delverng aie for st

  5. Slide 5: Executive Summary

    ® Executive Summary Y The Progenics Board heard the callfor change a the Annual Meeting and has taken major steps to address shareholder feedback The merger agreement with Lantheus reflects the culmination of thoughtful discussions and analysis between Progenics and Lantheus that started at the begi

  6. Slide 6: Executive Summary

    ———— Sa enn eo .¢ C - Executive Summary Y The combined company would be led by the current Lantheus Board and CEO who have a successful track record generating over 273% in returns for Lantheus shareholders Velan will only be satisfied by taking control of a majority of the Board (paying no control

  7. Slide 7: Lantheus, Progenics Combination Creates a Global Leader in Precision Diagnostics and Therapeutics

    Lantheus, Progenics Combination Creates a Global Leader in Precision Diagnostics and Therapeutics Committed to Creating Shareholder Value ¥ Ahighly complementary portfolio of ultrasound and 35% Strong Pro Forma radiopharmaceutical diagnostics and oncology ‘the ti Ownership Stake | _ Financial Profil

  8. Slide 8: Part I: Additional Change Is NOT Warranted

    Part I: Additional Change Is NOT Warranted

  9. Slide 9: In July, Shareholders Voted for Minority Change — PGNX Listened and Responded with Immediate Action

    ————— Sa enn yn ¢ In July, Shareholders Voted for Minority Change — PGNX Listened and « Responded with Immediate Action 2019 AGM ys ———> Today Shareholders Voted for Enhanced Oversight to Drive Sustainable Value and PGNX Took Action sats Progenics ¥ changein Board leadership withthe resignations of

  10. Slide 10: Combination with LNTH Accelerates Strategic Priorities and Creating Shareholder Value

    Combination with LNTH Accelerates Strategic Priorities and Creating « Shareholder Value In addition to enhanced oversight, PGNX has continued to execute onits strategic objectives. 2019 Key Mileston ¥ Recorded revenue onitstistcommerialsalesandcompletethefist, ‘Sdministations of commer AZEDRA tntiat

  11. Slide 11: Determined to Take Control, Velan Continues to Make Overstretched Arguments

    a 7\ le A z @ 5° Determined to Take Control, Velan Continues to Make Overstretched ¢ Arguments to Seek Disproportional Change e AsGlass Lewis noted, Velon’s “specious suggestons..are healy weighted towards hindsight" Velan's Criticisms PGNX Response Manapeetvas unable sucessfully execute on AZEDRAS

  12. Slide 12: Part II: The LNTH / PGNX Combination Provides the Best Path Forward

    Part Il: The LNTH / PGNX Combination Provides the « ; Best Path Forward Offering Substantial and Sustainable \ Value to Shareholders e Sa ‘ fe Progenics or e ) Find Fightan alow”

  13. Slide 13: Creating Substantial Value to Shareholders

    Creating Substantial Value to Shareholders 7 359% Lanter emt Compelling Transaction Structure siving equity holders a substantial ~V~ Lantheus to acquire 100% of PGNX's common shares ina tax-free allstock transaction Interest in the combined company ¥PGNX shareholders to receive 0.2502 Lantheus shar

  14. Slide 14: Complimentary Core Capabilities Making a Global Leader

    Complimentary Core Capabilities Making a Global Leader Core Capabilities and Infrastructure Management Team Synergies and Cash Flow Generation Progenics Robust oncology therapeutieportfolie with Azedra and 2095 Leading next-generationoncolegy diagnosticin PyL Key strategiepartnerships with Bayer, Ba

  15. Slide 15: The Transaction Provides Greater Value Opportunities for PGNX Shareholders Than as a Standalone Company

    The Transaction Provides Greater Value Opportunities for PGNX pw Shareholders Than as a Standalone Company e Value Creation as a Combined Company Progenics as a Standalone Company Identified synergies and cost avoidance amounting to $20mby 2022 and enhanced revenue growth from multiple products "= R

  16. Slide 16: Creating a Well-Balanced Portfolio of Diagnostics to Therapeutics

    Creating a Well-Balanced Portfolio of Diagnostics to Therapeutics Precision Diagnostics Oncology Denys peeell eo A QUADRAMET <> sire Teche ‘in v AZEDRA Tati Xenon Xe 133 Gas Trlscnio RELISTOR’ aBsl Gallium pr ostonad etynatrome tome ae F 18 injection Seren oF 18) AzeoRa REUSTOR QUADRAMET Automated B

  17. Slide 17: Announced Premium Inline with or Exceeds All-Stock Precedents

    Announced Premium Inline with or Exceeds All-Stock Precedents, with Potential for Future Stock Price Appreciation Remaining Intact 30-Trading Day Share Price Premium Inline with Premium Psidin Comparable llstock Precedents The transacti provides PGNX shareholders with an announced stock premium® inl

  18. Slide 18: Transaction Driving Value for Shareholders

    Transaction Driving Value for Shareholders ‘The Transaction Delivers Value to Shareholders Imped Transaction Premium to: 24% 23% aan ice n0% —= — co == em) S2wkintodey igh S2ukeitroday tow 0-raingDey —_—=0-Trxing Day SO Tracing Days ror 30 Tring Day rior. Seven Trading Doy ior Closing Sok ce (uo/as/

  19. Slide 19: Part III: The Transaction Process

    Part Ill: The Transaction Process ia é Progenics se gis Ps,

  20. Slide 20: Comprehensive Process to Maximize Shareholder Value

    Comprehensive Process to Maximize Shareholder Value Key Points Transaction Timeline Tan." tantheus nd progenies estat the Jp Healncareconfaencetodiniss waystowork together Ongoing discussions began before ary fate s¥BLeerinkontctsaProgencrBcatimembe the dieonofthantheustoerd, oreueranniedutontoMark

  21. Slide 21: Part IV: Shareholders Are Entitled to Full Disclosure on the Transaction

    Part IV: Shareholders Are Entitled to Full Disclosure on « ; the Transaction Before Making a Material Decision on aa the Company’s Future e ; 1, 4 Progenics wy » e 2 —) ind Fightand Flow”

  22. Slide 22: Shareholders Should Have Complete Information About the Transaction

    ———— SSS ern tos Shareholders Should Have Complete Information About the Transaction in Order to Make a Fully Informed Decision About the Composition of Progenics' Board Velan is wrongfully forcing shareholders into making a pivotal decision on the Company's future before allowing shareholders to ha

  23. Slide 23: Part V: Handing Control over to Velan Now Could Lead to Chaos and Value Destruction

    Part V: Handing Control over to Velan Now Could Lead to Chaos and Value Destruction Progenics Find Fight and Foltow*

  24. Slide 24: For Velan, Board Control Outweighs Enhancing Value for ALL Shareholders

    Nee “wi ” For Velan, Board Control Outweighs Enhancing Value for ALL Shareholders Velan's actions show a lack of concern for other shareholders and aselfindulgent fight for Board control r i saldatreudesa | “ . | Véanmakesmisatingand contacting | Velan has proven they will consider nothing less than

  25. Slide 25: The Argument Against the Transaction Being Approved by Two Resigning Directors is a Red-Herring

    ——————— eee nr @ 6° The Argument Against the Transaction Being Approved by Two « Resigning Directors is a Red-Herring ¢ The transaction wasunder discussion before Velan’s initial engagement with PGNX Involvement Since Pre-Velan Engagement Both Peter Crowley and Michael Kishbauch, as sitting Director

  26. Slide 26: A Successful Consent Solicitation by Velan Burdens Shareholders with Risk and Uncertainty

    ————— Sa eenrnrn A Successful Consent Solicitation by Velan Burdens Shareholders with Risk and Uncertainty for the Future If Velan Succeeds in Their Consent Solicitation AND Rejects the Transaction... Unestablished Leadership Lack of Strategy Financial Constraints % Current Board replaced with x Rec

  27. Slide 27: Velan Has Consistently Sought Disproportionate Influence

    Velan Has Consistently Sought Disproportionate Influence June, 2019 OFFER REJECTED ‘rogenics Final Settlement Offer Before the AGRA 33% soporezotavein pris, 2019 Api28, 019 Api, 2050, mae “toa merits ting hereto ropes apes tohve mse =. reaconbi srt ot setter mee tO that ny ear adequate stent rere th

  28. Slide 28: Part VI: A Board and Management Team Poised to Create Shareholder Value

    Part VI: A Board and Management Team Poised to 5 Create Shareholder Value \e "¢ Progenics Find Fight and Follow”

  29. Slide 29: Highly Experienced and Accomplished Board...

    Highly Experienced and Accomplished Board... Pro forma Lantheus + Progenics Board Well-balanced and highly qualified Board Lantheus' Board will remain intact with the addition of Progenics’ independent Director, Bradley Campbell, Director backgrounds are diverse and complementary, bringing together

  30. Slide 30: .. That Delivers Shareholder Value

    .. That Delivers Shareholder Value = = Le == _ Ss ‘Mary Anne Heino srai201s, 28708 idl ‘Brian Markison 9/6/2012 27378 i i wv ~ fl 7 oe v v v v ‘Samuelteno- sro 27378 ts - v Julie McHugh 423/2027 181% v a aa of v ean = v v Z v omdin a y v Z Or. FrederickRobertson 9/4/2016 107.9% ci Ca - = we voenesin

  31. Slide 31: The Combined Company Is Led by an Experienced Leadership Team

    The Combined Company Is Led by an Experienced Leadership Team John Bolla Chief Operations officer Former VB Supply Chon North America ot GSK ‘among other senior leadership roles ¥ 22 years of diverse supply chen, operations ond ‘manufacturing experience Inthe pharma Inductry Mary Anne Heino Presiden

  32. Slide 32: Combined Board and Corporate Governance Highlights

    —————— Sane nr yA ¢ Combined Board and Corporate Governance Highlights ms Board Highlights Corporate Governance Highlights Chairman: Independent Y Ability to call special meetings (50.19%) Board Size: 11 ¥ Ability to approve mergers by majority vote Average Director tenure: 3.1 years) Pro forma Dire

  33. Slide 33: A Combination with Lantheus Accelerates Strategic Priorities Focused on Creating Long-term Shareholder Value

    A Combination with Lantheus Accelerates Strategic Priorities Focused « on Creating Long-term Shareholder Value Y Ahighly complementary portfolio of ultrasound and radiopharmaceutical diagnostics and oncology therapeutics Y Diversified revenue streams, enhanced cashflow generation, eliminated future

  34. Slide 34: Shareholders Voted — PGNX Continues to Execute

    Shareholders Voted — PGNX Continues to Execute s VF shemoxeiies pod hear ihecaliorGimgestshenrneil vectingand laxeelmemaloemapsto-aiiresshatholder Leihad v ‘The Lantheus transaction reflects the culmination of thoughtful discussion and analysis between Progenics and Lantheus far preceding any engage

  35. Slide 35: Appendix

    Appendix

  36. Slide 36: While the Oncology Biopharma Industry Has Experienced Challenges, PGNX Has Performed In-Line with Peers

    While the Oncology Biopharma Industry Has Experienced Challenges, PGNX Has Performed Largely In-Line with Peers... 1, 3:, 5-Year TSR to 1-Day Prior to Lantheus Deal Announcement smProny Peer) mmal-ap Onclegy Biopharma) mPGNX eer Year S-Y00r os = (3%) - a7) tom ex 2) wo oo om) rove —<_ =e a vant gw n

  37. Slide 37: Increasing Value Through Synergy and Capital Enhancement

    —————— Saas nr ee. Increasing Value Through Synergy and Capital Enhancement Pe Strategi Financial Near Term successful tackrecord of product commerealization Effective Board oversight with strong snced management team with 2 . 1d operational execution commercial, operational and financial expertise

  38. Slide 38: Combination Drives Value Creation Across Multiple Fronts

    Combination Drives Value Creation Across Multiple Fronts Transactions atthe forefront ofradlopharma's trajectory ~ combining diagnostics and therapeutics to improve patent care Robust & Complementary Portfolio of Assets Complementary portfolio of ultrasound and radiopharmaceutcal diagnostics and onc

  39. Slide 39: The Transaction Provides a Robust Pipeline with Clear Value Drivers

    ® The Transaction Provides a Robust Pipeline with Clear Value Drivers Ee dr + wrnienee 2: tenrrenvremaenn lll OCC COOL LLDCS a es Bergen / a te | Sco y SE [ceseecneececeenerrer] es

  40. Slide 40: The Transaction Provides a Strong Financial Outlook

    ———— Saar een e@ 6° The Transaction Provides a Strong Financial Outlook Pe Increased Gross Margins Accretive to LNTH's EPS Cash Flow Generating Increasing ROIC AHealthy Balance Sheet The transaction puts the combined company in a financ {Gross margin improvement through enhanced revenue growth and r

  41. Slide 41: Endocyte's Sale Price is Not Comparable to Progenics

    Endocyte’s Sale Price is Not Comparable to Progenics Given Differences in Probability of Success Driven by POC Data and Phase of Development Endocyte — Enterprise Value (TEV) ce) 1 “noraeesretaratentaio! |1 encoenefotevot ae ' Pane, 1 eSsblion Lo i 1 __sevotgriamaitn HSRC roves satosnounga 758 omen

  42. Slide 42: Termination fee is inline with industry precedents

    ————————— eer enn e@ 6° Termination fee is inline with industry precedents and not tied to « Progenics shareholder approval ¢ * Company termination fee of $18,340,000is payableit: = Agreementis terminated dueto i) a willful and material violation of the non-solicitor i) Progenics’ board fallsto reco

  43. Slide 43: Peer Groups

    Peer Groups asiePharmacestia ne oe sda ne satus Therapeutes Pe Sponored 208 eondoring ne 0m Therapeutics, ne DacphraPhccoutia ne Engle Pharmaceutea ne HarpsonTherepewes ne. denateerapetis, ne ene In Semline Terps ‘oRa Therapies ne syns, ne pues ie ‘oncom harmaceucal in. ge Pharmaceuticals ine sucopo

Progenics Pharmaceuticals — Proxy Contest (October 2019) on 6ix